These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18718922)

  • 21. Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.
    Doyle T; Dunn DT; Ceccherini-Silberstein F; De Mendoza C; Garcia F; Smit E; Fearnhill E; Marcelin AG; Martinez-Picado J; Kaiser R; Geretti AM;
    J Antimicrob Chemother; 2015 Nov; 70(11):3080-6. PubMed ID: 26311843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
    Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
    AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
    Charpentier C; Malet I; Andre-Garnier E; Storto A; Bocket L; Amiel C; Morand-Joubert L; Tumiotto C; Nguyen T; Maillard A; Rodallec A; Leoz M; Montes B; Schneider V; Plantier JC; Dina J; Pallier C; Mirand A; Roussel C; Signori-Schmuck A; Raymond S; Calvez V; Delaugerre C; Marcelin AG; Descamps D
    J Antimicrob Chemother; 2018 Apr; 73(4):1039-1044. PubMed ID: 29342281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combined genotypic and phenotypic human immunodeficiency virus type 1 recombinant virus assay for the reverse transcriptase and integrase genes.
    Van Baelen K; Rondelez E; Van Eygen V; Ariën K; Clynhens M; Van den Zegel P; Winters B; Stuyver LJ
    J Virol Methods; 2009 Nov; 161(2):231-9. PubMed ID: 19559730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain.
    Le Hingrat Q; Collin G; Lê M; Peytavin G; Visseaux B; Bertine M; Tubiana R; Karmochkine M; Valin N; Collin F; Lemaignen A; Bernard L; Damond F; Matheron S; Descamps D; Charpentier C;
    Clin Infect Dis; 2019 Aug; 69(4):657-667. PubMed ID: 30383215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
    Varghese V; Liu TF; Rhee SY; Libiran P; Trevino C; Fessel WJ; Shafer RW
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1323-6. PubMed ID: 20961278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
    Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
    J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrase inhibitors: a novel class of antiretroviral agents.
    Schafer JJ; Squires KE
    Ann Pharmacother; 2010 Jan; 44(1):145-56. PubMed ID: 20040702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 Group O Resistance Against Integrase Inhibitors.
    Depatureaux A; Mesplède T; Quashie P; Oliveira M; Moisi D; Plantier JC; Brenner B; Wainberg MA
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):9-15. PubMed ID: 26017662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
    Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
    AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
    Malet I; Wirden M; Fourati S; Armenia D; Masquelier B; Fabeni L; Sayon S; Katlama C; Perno CF; Calvez V; Marcelin AG; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2011 Jul; 66(7):1481-3. PubMed ID: 21474479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors.
    Goethals O; Clayton R; Van Ginderen M; Vereycken I; Wagemans E; Geluykens P; Dockx K; Strijbos R; Smits V; Vos A; Meersseman G; Jochmans D; Vermeire K; Schols D; Hallenberger S; Hertogs K
    J Virol; 2008 Nov; 82(21):10366-74. PubMed ID: 18715920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals.
    Dimonte S; Babakir-Mina M; Aquaro S; Perno CF
    Infection; 2013 Dec; 41(6):1097-102. PubMed ID: 23620062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
    Llácer Delicado T; Torrecilla E; Holguín Á
    J Antimicrob Chemother; 2016 Feb; 71(2):362-6. PubMed ID: 26546669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.